We are a prominent private primary and secondary education service provider in Lishui City, Zhejiang Province. According to the Frost & Sullivan report, we were one of the top ten private primary and secondary education institutes in Zhejiang Province in terms of the students enrolled on a monthly average basis for the 2019/2020 school year.
Unit offering: Each Consisting of One 7.75% Series A Cumulative Convertible Preferred Share and Eight Warrants
FOLLOW-ON UPLISTING: Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment.
We are a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated.
Early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X tremor-ataxia syndrome (or FXTAS). Each share of our common stock is being sold together with three quarters of one warrant to purchase one share of common stock.
We are a cutting-edge wellness hemp-derived cannabidiol, or CBD, consumer product development company. We are in the early stage of manufacturing, distributing, and marketing a diverse line of consumer products infused with CBD. We are offering 1,000,000 units (each, a “Unit”), each Unit consisting of one share of common stock, par value $0.001 per share, and one warrant (each a “Warrant”), in a firm commitment initial public offering at an assumed price of US$7.50 per Unit.
We are a household service company based in Fuzhou, China. We provide integrated household services through our website and WeChat platform, “e家快服”, across 32 provinces in China.
Boqii is the largest pet-focused platform in China, in terms of revenue in 2019 and number of customers as of December 31, 2019, according to Frost & Sullivan.
BlackRock Capital Allocation Trust (the “Trust”) is a newly-organized, non-diversified, closed-end management investment company with no operating history. The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
An artificial intelligence driven platform and course designer that rapidly provides customized, high performance and scalable online products for schools and businesses. We use machine learning to provide a novel, mass customized experience to learners. Our customers are businesses, universities and colleges and K-12 schools.
Follow-on offering and simultaneous up-listing for Jerrick Media Holdings, Inc. which currently trades on the OTCQB under the ticker “JMDAD.” Upon completion of the offering, the Company anticipates changing its name to “Creatd, Inc.” while the shares and warrants issued in the offering will trade under the symbol “CRTD” and “CRTDW.”
Industrial Tech Acquisitions, Inc. is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to as our initial business combination.
Develops, designs and manufactures disinfection systems, that eliminate pathogens that may cause healthcare-acquired infections (“HAIs”),
Series A Cumulative Redeemable Perpetual Preferred Stock
The company has developed the Audience Cloud, a modular, highly scalable, transparent, cloud-based software platform for real-time trading of digital, programmatic advertising.
We are a provider of financial and transaction services in the People’s Republic of China (“PRC” or “China”) and principally operate in two business segments: online peer-to-peer (“P2P”) lending and automobile transaction and financing services.
We are a clinical-stage biopharmaceutical company committed to developing new generation therapies for anxiety, depression and certain additional central nervous system (CNS) disorders for which we believe current treatment options are inadequate, resulting in high unmet need in large and growing markets worldwide.
The offering price is determined by the underwriter and is normally based on numerous factors such as company’s financials, its future perspectives and risks, as well as demand for the company shares.The price determined should be high enough for the company to raise sufficient capital, while representing a fair value of the shares for potential investors.